Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $694000.0.

  • Regenxbio's Change in Account Payables fell 7778.49% to $694000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 22393.36%. This contributed to the annual value of -$292000.0 for FY2024, which is 8953.78% up from last year.
  • Regenxbio's Change in Account Payables amounted to $694000.0 in Q3 2025, which was down 7778.49% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Change in Account Payables ranged from a high of $16.8 million in Q1 2022 and a low of -$14.9 million during Q2 2024
  • Moreover, its 5-year median value for Change in Account Payables was $1.2 million (2023), whereas its average is $683157.9.
  • Examining YoY changes over the last 5 years, Regenxbio's Change in Account Payables showed a top increase of 592697.84% in 2022 and a maximum decrease of 54248.89% in 2022.
  • Regenxbio's Change in Account Payables (Quarter) stood at -$8.8 million in 2021, then skyrocketed by 121.65% to $1.9 million in 2022, then tumbled by 36.03% to $1.2 million in 2023, then surged by 149.02% to $3.0 million in 2024, then plummeted by 77.16% to $694000.0 in 2025.
  • Its last three reported values are $694000.0 in Q3 2025, $2.5 million for Q2 2025, and -$3.7 million during Q1 2025.